Kraj: Kanada
Język: angielski
Źródło: Health Canada
DONEPEZIL HYDROCHLORIDE
SUN PHARMA CANADA INC
N06DA02
DONEPEZIL
10MG
TABLET
DONEPEZIL HYDROCHLORIDE 10MG
ORAL
100/500
Prescription
PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS
Active ingredient group (AIG) number: 0131548002; AHFS:
APPROVED
2020-03-10
Page 1 of 52 PRODUCT MONOGRAPH PR TARO-DONEPEZIL Donepezil Hydrochloride Tablets, House Std 5 and 10 mg CHOLINESTERASE INHIBITOR Sun Pharma Canada Inc. Date of Revision: March 6, 2020 126 East Drive Brampton, Ontario L6T 1C1 Submission Control No.: 236591 Page 2 of 52 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................ 3 INDICATIONS AND CLINICAL USE .................................................................................. 3 CONTRAINDICATIONS ........................................................................................................ 3 WARNINGS AND PRECAUTIONS ....................................................................................... 3 ADVERSE REACTIONS ......................................................................................................... 8 DRUG INTERACTIONS ....................................................................................................... 17 DOSAGE AND ADMINISTRATION ................................................................................... 18 OVERDOSAGE ...................................................................................................................... 19 ACTION AND CLINICAL PHARMACOLOGY ............................................................... 20 STORAGE AND STABILITY ............................................................................................... 22 DOSAGE FORMS, COMPOSITION AND PACKAGING ................................................ 22 PART II: SCIENTIFIC INFORMATION ............................................................................... 24 PHARMACEUTICAL INFORMATION ............................................................................. 24 CLINICAL TRIALS ............................................................................................................... 25 DETAILED PHARMACOLOGY .............. Przeczytaj cały dokument